Per una migliore esperienza, mantieni il tuo browser aggiornato. Controlla qui le ultime versioni.

November 2020
Diadem Names Clinical Diagnostics Industry Veteran Paul Kinnon as CEO
Kinnon Joins to Lead Development and Commercialization of First Minimally Invasive Blood-Based Prognostic Test for Early Alzheimer’s Disease.

Diadem, a company developing the first blood-based test for the prediction of early onset Alzheimer’s disease, announced that Paul Kinnon has been named Chief Executive Officer.

Mr. Kinnon brings Diadem extensive global executive experience in successfully developing and commercializing innovative diagnostic and life science technologies in Europe and the U.S.

Alzheimer’s disease and other dementias are among the greatest public health crises of our time, afflicting more than 50 million people worldwide. Development of effective therapies has been hindered by the difficulty of prediction and diagnosis, which makes early, effective intervention impossible.
Paul Kinnon
CEO @ Diadem

Diadem’s transformational technology for the first time makes it possible to diagnose Alzheimer’s early in the disease process and to predict whether the disease will progress. This will allow patients to seek treatment at a time when it is still possible to impact disease progression and preserve function.

Kinnon served as chief executive officer at PredictImmune, publicly traded Transgenomic, and ZyGEM Corp. He held senior executive positions at Life Technologies (now ThermoFisher), Guava Technologies and Cellomics, raising substantial funding, creating global partnerships and increasing shareholder returns. Kinnon has a proven strategic and commercialisation track record of developing and bringing novel technologies and products to global markets rapidly and efficiently. He serves on the boards of both public and private companies and has significant expertise in corporate governance, corporate restructuring, and M&A and divestitures.